The unlikely combination: Anderson-Fabry disease and congenital dyserythropoietic anemia type II in a pediatric patient

被引:1
作者
Elsherif, Yasmine [1 ]
Ibrahim, Ismail A. [2 ]
Elsherif, Omar [3 ]
Abukhadijah, Hana J. [4 ]
机构
[1] Amer Hosp Dubai AHD, Internal Med, Dubai, U Arab Emirates
[2] Fenerbahce Univ, Fac Hlth Sci, Istanbul, Turkiye
[3] Tbilisi State Med Univ, Tbilisi, Georgia
[4] Hamad Med Corp, Acad Hlth Syst Dept, Doha 3050, Qatar
关键词
Anderson-Fabry disease; CDA type II; congenital dyserythropoietic anemia; co-occurrence; genetic distinction; lysosomal disorder; NATURAL-HISTORY; CHILDREN; MUTATIONS; THERAPY;
D O I
10.1002/ccr3.9354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anderson- Fabry disease (AFD) is a rare condition, characterized by a lysosomal storage disorder affecting lipid storage. It manifests in two forms: classic (early- onset) and nonclassic (late- onset). Conversely, congenital dyserythropoietic anemia (CDA) is a rare blood disorder caused by ineffective erythropoiesis, which results in the production of abnormal erythroblasts during the maturation of red blood cells, with CDA type II being the most frequent type. Both disorders have well- understood pathophysiologies, yet they are genetically distinct. AFD is inherited in an X- linked manner, whereas CDA type II follows an autosomal recessive pattern of inheritance. Although both AFD and CDA type II have been reported separately in the literature. The co- existence for both AFD and CDA type II has not been reported. We describe a 10- year- old boy, with both which is believed to be the first documented case.
引用
收藏
页数:5
相关论文
共 23 条
[1]   Enzyme replacement therapy for Fabry disease: some answers but more questions [J].
Alfadhel, Majid ;
Sirrs, Sandra .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 :69-82
[2]   Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course [J].
Branton, MH ;
Schiffmann, R ;
Sabnis, SG ;
Murray, GJ ;
Quirk, JM ;
Altarescu, G ;
Goldfarb, L ;
Brady, RO ;
Balow, JE ;
Austin, HA ;
Kopp, JB .
MEDICINE, 2002, 81 (02) :122-138
[3]   Radiological evidence of early cerebral microvascular disease in young children with Fabry disease [J].
Cabrera-Salazar, MA ;
O'Rourke, E ;
Charria-Ortiz, G ;
Barranger, JA .
JOURNAL OF PEDIATRICS, 2005, 147 (01) :102-105
[4]   Co-existence of Phenylketonuria and Fabry disease on a 3 year-old boy: case report [J].
Concolino, Daniela ;
Rapsomaniki, Maria ;
Disabella, Eliana ;
Sestito, Simona ;
Pascale, Maria G. ;
Moricca, Maria T. ;
Bonapace, Giuseppe ;
Arbustini, Elisea ;
Strisciuglio, Pietro .
BMC PEDIATRICS, 2010, 10
[5]   Lentiviral Gene Therapy for the Correction of Congenital Dyserythropoietic Anemia Type II [J].
Dessy-Rodriguez, Mercedes ;
Fañanas-Baquero, Sara ;
Venturi, Veronica ;
Payan, Salvador ;
Tornador, Cristian ;
Hernández, Gonzalo ;
Bianchi, Paola ;
Sanchez, Mayka ;
Ramirez, Juan Carlos ;
Segovia, José C. ;
Bustamante, Oscar Quintana .
BLOOD, 2021, 138 :1994-+
[6]   Paediatric Fabry disease [J].
Ellaway, Carolyn .
TRANSLATIONAL PEDIATRICS, 2016, 5 (01) :37-42
[7]   Diagnostic dilemma and delay in Fabry disease: Insights from a case series of young female patients [J].
Ellaway, Carolyn .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2015, 51 (04) :369-372
[8]   Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients [J].
Germain, Dominique P. ;
Fouilhoux, Alain ;
Decramer, Stephane ;
Tardieu, Marine ;
Pillet, Pascal ;
Fila, Marc ;
Rivera, Serge ;
Deschenes, Georges ;
Lacombe, Didier .
CLINICAL GENETICS, 2019, 96 (02) :107-117
[9]   Congenital dyserythropoietic anemia type I with bone abnormalities, mutations of the CDAN I gene, and significant responsiveness to alpha-interferon therapy [J].
Goede, Jeroen S. ;
Benz, Rudolf ;
Fehr, Joerg ;
Schwarz, Klaus ;
Heimpel, Hermann .
ANNALS OF HEMATOLOGY, 2006, 85 (09) :591-595
[10]  
Havranek S, 2013, JIMD REP, V11, P53, DOI 10.1007/8904_2013_222